Particularly because there is a significant correlation of lymphatic PD-1 or CTLA-4 with lymphatic NR2F6 expression in human NSCLC patients [30], we wanted to determine whether acute Nr2f6 inactivation enables anti-cancer activity in vivo. This evidence concerns the gene CTLA4 and cancer.